Agilent Technologies
About: Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools, cross lab consisting of consumables and services related to life science and applied tools, and diagnostics and genomics. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.
Employees: 17,400
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
35% more first-time investments, than exits
New positions opened: 130 | Existing positions closed: 96
9% more capital invested
Capital invested by funds: $33.6B [Q2] → $36.7B (+$3.05B) [Q3]
3% more funds holding
Funds holding: 994 [Q2] → 1,028 (+34) [Q3]
10% less repeat investments, than reductions
Existing positions increased: 339 | Existing positions reduced: 375
4.03% less ownership
Funds ownership: 89.02% [Q2] → 85.0% (-4.03%) [Q3]
8% less funds holding in top 10
Funds holding in top 10: 13 [Q2] → 12 (-1) [Q3]
24% less call options, than puts
Call options by funds: $122M | Put options by funds: $162M
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
6 analyst ratings
B of A Securities Derik De Bruin 32% 1-year accuracy 6 / 19 met price target | 12%upside $150 | Neutral Maintained | 13 Dec 2024 |
Wells Fargo Brandon Couillard 28% 1-year accuracy 5 / 18 met price target | 15%upside $155 | Overweight Maintained | 9 Dec 2024 |
Barclays Luke Sergott 27% 1-year accuracy 13 / 48 met price target | 0%upside $135 | Underweight Maintained | 27 Nov 2024 |
Bernstein Eve Burstein 67% 1-year accuracy 4 / 6 met price target | 0%upside $135 | Market Perform Maintained | 26 Nov 2024 |
JP Morgan Rachel Vatnsdal 47% 1-year accuracy 8 / 17 met price target | 19%upside $160 | Overweight Maintained | 26 Nov 2024 |
Financial journalist opinion
Based on 17 articles about A published over the past 30 days